How it works
It combines GLP-1's appetite and glucose effects with glucagon-receptor activity thought to raise energy expenditure and act on the liver — a different pairing from tirzepatide's GLP-1/GIP.
The evidence
Trials report substantial weight loss and encouraging liver-disease (MASH) signals, but it remains investigational. As always, trial averages are not individual promises.
Safety
Predominantly gastrointestinal side effects, with metabolic monitoring given glucagon activity. Human long-term safety is still being characterized.
FAQ
Survodutide is a dual (GLP-1 + glucagon) agonist; retatrutide adds GIP for a triple. Different receptor mixes.
No — investigational, in Phase 3.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Retatrutide/survodutide status overview (Drugs.com)
- GI adverse events with GLP-1 RA: meta-analysis (Int. J. Obesity)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Remy — part of the PepConnection crew.